Realizing the urgent unmet medical need created by the 2019 SARS-CoV-2 pandemic, Relief mounted a swift plan of action to respond to one of the largest healthcare disasters of our time by rapidly advancing our proprietary asset RLF-100™ into clinical development and towards approval in COVID-19 induced lung injury. RLF-100™ is outpacing traditional clinical development timelines to meet the necessary safety and efficacy requirements.